LCL-161

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameLCL-161
Drug Alias NameSecond Mitochondria-derived Activator of Caspases (SMAC) mimetic - Novartis OncologySMAC mimetic LCL161LCL-161
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActioncIAP1/cIAP2 inhibitors
TargetscIAP1/cIAP2
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisSmall Cell Lung Carcinoma +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesNational Cancer InstituteUs Oncology Research LlcMayo Clinic
Active IndicationsPrimary MyelofibrosisPolycythemia VeraDigestive System Neoplasms
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaOvarian Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A